Patient P-01746
Therapy response
Stable
Tolerance
Improving
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Improving
Discontinuation risk
74%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 GI symptom burden −25% vs expected — Dietary Support Protocol NP-02
- Day 48 Tolerance state changed — Unstable → Improving
- Day 55 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 68 ME-01 recommended — Monitoring Escalation ME-01
- Day 69 Patient accepted — Started ME-01 in the companion
- Day 72 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 55.
Primary contributors, last 14 days
- GI instability-25
- Inflammatory activity-22
- Nutritional resilience+10
- Toxicity-8
What helped?
- Dietary Support Protocol NP-02Day 31Result: symptom burden −25%
- Monitoring Escalation ME-01Day 68Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
80%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 84% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 22/100
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3.1 · butyrate capacity 22/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 53 ms
- Sleep
- 6.4 h
- Steps
- 3,767
- Resting HR
- 68 bpm
Daily log: GI score 40, nutritional resilience 51, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.